Boston Metal is most of the way to a $60m target for its latest round, thanks to a consortium that included returning backer The Engine.

University of Oxford’s autonomous driving software developer Oxbotica has secured $47m in a series B round featuring IP Group as well as several corporates.

The oncolytic virus therapy-based cancer drug developer is based on research at Salk Institute and has raised $77m in its series A round.

U-M's retinal disease drug developer has secured $46.9m of series B capital from investors including Mints.

Citi Impact Fund helped supply $60m to help MIT’s smart scooter provider Superpedestrian hike its overall funding to about $140m.

Tokyo University of Science helped extend Gojo & Company's series D round to $68.6m, lifting the microfinancing provider's overall funding to around $142m.

University of Florida has backed a second round for Atsena, a vision loss therapy developer exploiting inventions the institution had originally licensed to Sanofi.

The neurodegenerative disorder drug developer has emerged from stealth to commercialise Howard Hughes Medical Institute research.

The rocket launcher spinout of TUM has received $90.8m in a UVC Partners-backed round as it prepares for a first commercial launch in 2022.

University of Oxford joined Oxford Sciences Innovation to back neuromuscular disease therapy spinout PepGen, which will move its base to the US.